HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Lexicon Pharmaceuticals, maintaining a $10 price target.
October 03, 2024 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Lexicon Pharmaceuticals, maintaining a $10 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $10 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Lexicon Pharmaceuticals' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100